Vicebio Secures $100 Million to Revolutionize Vaccine Production

Vicebio, a London-based biotechnology startup, has secured $100 million in Series B financing to revolutionize vaccine production. This funding will support the development of innovative and cost-effective vaccines, including a promising combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus. With a novel ‘molecular clamp’ technology, Vicebio aims to enhance immune responses while simplifying manufacturing processes, positioning itself as a leader in affordable vaccine solutions amidst rising demand for respiratory infection prevention.